Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing
Jessica L. Mester(West Coast University), Kathleen S. Hruska, Jeffrey Bissonnette, Kristen J. Vogel Postula, Patricia D. Murphy(Newark Beth Israel Medical Center), Sarah A. Jackson, Sheila Solomon, Rachel T. Klein, Amy Stettner
Cited by 23
Related Papers
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.
|PubMed|1989|963
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing
|Genetics in Medicine|2015|292
Genetic Information and the Workplace: Legislative Approaches and Policy Challenges
|Science|1997|153
Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer
|The American Journal of Human Genetics|2015|92